Prognostic value of TLR from FDG PET/CT in patients with margin-negative stage IB and IIA non-small cell lung cancer
- PMID: 37060445
- DOI: 10.1007/s00330-023-09641-w
Prognostic value of TLR from FDG PET/CT in patients with margin-negative stage IB and IIA non-small cell lung cancer
Abstract
Objectives: To evaluate the prognostic value of TLR from PET/CT in patients with resection margin-negative stage IB and IIA non-small cell lung cancer (NSCLC) and compare high-risk factors necessitating adjuvant treatment (AT).
Methods: Consecutive FDG PET/CT scans performed for the initial staging of NSCLC stage IB and IIA were retrospectively reviewed. The maximum standardized uptake value (SUVmax) of the primary tumor and mean SUV of the liver were acquired. The tumor-to-liver SUV ratio (TLR) was also calculated. Charts were reviewed for basic patient characteristics and high-risk factors for considering AT (poor differentiation, visceral pleura invasion, vascular invasion, tumors > 4 cm, and wedge resection). Statistical analysis was performed using Cox regression analysis and the Kaplan-Meier method.
Results: Of the 112 patients included, 15 (13.4%) died, with a median overall survival (OS) of 43.8 months. Twenty-two patients (19.6%) exhibited recurrence, with median disease-free survival (DFS) of 36.0 months. In univariable analysis, pathology, poor differentiation, and TLR were associated with shorter DFS and OS. In multivariable analysis, TLR (hazard ratio [HR] = 1.263, p = 0.008) and differentiation (HR = 3.087, p = 0.012) were associated with shorter DFS. Also, TLR (HR = 1.422, p < 0.001) was associated with shorter OS.
Conclusion: TLR from FDG PET/CT was an independent prognostic factor for recurrence and survival. PET parameters constitute risk factors for consideration in the decision-making for AT in margin-negative stage IB and IIA NSCLC.
Clinical relevance statement: In this study, TLR from FDG PET/CT was an independent prognostic factor in stage IB-IIA non-small cell cancer patients. Although additional validation studies are warranted, TLR has the potential to be used to determine the need for adjuvant therapy.
Key points: • High TLR is an independent poor prognostic factor in stage IB-IIA NSCLC. • Adjuvant treatment should be considered in patients with high TLR following complete tumor resection.
Keywords: Adjuvant treatment; Carcinoma, non-small cell lung; Positron Emission Tomography Computed Tomography; Prognosis; Stage IB-IIA.
© 2023. The Author(s), under exclusive licence to European Society of Radiology.
Similar articles
-
Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage IA non-small cell lung cancer patients?J Cancer Res Clin Oncol. 2019 Apr;145(4):1021-1026. doi: 10.1007/s00432-019-02858-7. Epub 2019 Feb 13. J Cancer Res Clin Oncol. 2019. PMID: 30756189 Free PMC article.
-
Elevated tumor-to-liver uptake ratio (TLR) from 18F-FDG-PET/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection.Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):1958-1968. doi: 10.1007/s00259-017-3779-0. Epub 2017 Aug 15. Eur J Nucl Med Mol Imaging. 2017. PMID: 28812134 Free PMC article.
-
Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19. Acad Radiol. 2013. PMID: 22999369
-
Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: A systematic review and meta-analysis.Radiother Oncol. 2020 Oct;151:152-175. doi: 10.1016/j.radonc.2020.07.030. Epub 2020 Jul 22. Radiother Oncol. 2020. PMID: 32710990
-
Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity-matched analysis in a cohort of 147 recurrences.Thorac Cancer. 2022 Nov;13(22):3105-3113. doi: 10.1111/1759-7714.14659. Epub 2022 Sep 14. Thorac Cancer. 2022. PMID: 36104006 Free PMC article. Review.
Cited by
-
Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer.Front Med (Lausanne). 2025 Jan 31;12:1477275. doi: 10.3389/fmed.2025.1477275. eCollection 2025. Front Med (Lausanne). 2025. PMID: 39958820 Free PMC article.
References
-
- Postmus PE, Kerr KM, Oudkerk M et al (2017) Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv1-iv21
-
- National Comprehensive Cancer Network Non-Small Cell Lung Cancer (Version3.2022). Available via https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf . Accessed 3 June 2022
-
- Zuo Z, Zhang G, Song P et al (2021) Survival nomogram for stage IB non-small-cell lung cancer patients, based on the SEER database and an external validation cohort. Ann Surg Oncol 28:3941–3950 - PubMed
-
- Okiror L, Harling L, Toufektzian L et al (2018) Prognostic factors including lymphovascular invasion on survival for resected non-small cell lung cancer. J Thorac Cardiovasc Surg 156:785–793 - PubMed
-
- Mollberg NM, Bennette C, Howell E, Backhus L, Devine B, Ferguson MK (2014) Lymphovascular invasion as a prognostic indicator in stage I non-small cell lung cancer: a systematic review and meta-analysis. Ann Thorac Surg 97:965–971 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical